Precision BioSciences reported third-quarter 2026 results alongside updates on its two clinical programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The company said it has $108 million in cash, cash equivalents and restricted cash, which it expects to fund operations through 2028 and support multiple clinical data readouts.
The near-term milestone is an upcoming presentation of PBGENE-HBV trial data. The company also began dosing the first participant in its Phase 1/2 study of PBGENE-DMD.
Key details
-
PBGENE-HBV data presentation set for Nov. 8: Late-breaking results from the ELIMINATE-B trial are scheduled for an oral presentation at the American Association for the Study of Liver Diseases’ Liver Meeting. The presentation is set for 2:15 p.m. Mountain time and will be delivered by the trial’s lead investigator, Man Fung Yuen of the University of Hong Kong and Queen Mary Hospital. The data abstract is scheduled for release Nov. 5.
-
First participant dosed in the PBGENE-DMD study: The first patient has been dosed at Arkansas Children’s Hospital in the Phase 1/2 FUNCTION-DMD trial. The company is targeting initial safety data by the end of 2026.
-
Cash and expected runway: Precision had $108 million in cash, cash equivalents and restricted cash at Sept. 30. It expects that balance to provide runway through 2028, including support for multiple clinical data readouts from PBGENE-HBV and PBGENE-DMD.
-
Company focus: Precision is a clinical-stage gene-editing company developing in vivo therapies using its ARCUS platform.
What changes for investors
The announcement adds a near-term clinical milestone for PBGENE-HBV and confirms that the PBGENE-DMD study has moved into patient dosing. The company’s stated cash runway through 2028 is intended to support further data from both programs.